Sermorelin 5mg

Description

Detailed Description

Sermorelin is a synthetic analog of the natural GHRH, featuring the first 29 amino acids from the typical 44 found in GHRH. Researchers propose that Sermorelin interacts with GHRH receptors on the pituitary gland, potentially triggering growth hormone secretion. Despite its shorter sequence, Sermorelin is believed to maintain the essential functions of GHRH by engaging these receptors and prompting periodic growth hormone release. This mechanism is thought to enhance levels of insulin-like growth factor-1 (IGF-1), which is crucial for the anabolic activities of growth hormone. The half-life of Sermorelin is estimated to be approximately 11 to 12 minutes.

One notable potential benefit of Sermorelin is its apparent specificity for GHRH receptors, suggesting it does not significantly alter levels of other endocrine markers such as prolactin, insulin, cortisol, glucose, or thyroid hormones.

Chemical Composition

• Molecular Formula: C149H246N44O42S
• Molecular Weight: 3357.93 g/mol
• Alternative Names: GRF 1-29

Research and Clinical Studies

Interaction with GHRH Receptors

Sermorelin is believed to interact with GHRH receptors, potentially initiating complex molecular signaling pathways. Upon binding, it may alter the receptor structure, leading to a cascade of intracellular events. Some studies suggest that Sermorelin might enhance the production of cyclic adenosine monophosphate (cAMP) in certain cells, possibly through the activation of adenylate cyclase, which converts ATP to cAMP. Elevated cAMP levels may activate protein kinase A (PKA), a crucial enzyme in cellular signaling. PKA could then phosphorylate target proteins, initiating further cellular responses. This proposed activation of GHRH receptors and the subsequent cAMP-PKA pathway might promote the secretion and distribution of growth hormone (hGH) from pituitary somatotroph cells, which in turn could stimulate the synthesis of IGF-1.

Impact on Growth Velocity

Research indicates positive outcomes in models of idiopathic growth hormone deficiency when Sermorelin was administered to underdeveloped animal subjects. These models showed increased growth and height velocity over a 12-month period with continuous peptide presence, and these elevated levels were sustained for an average of 36 months.

Anabolic Research Outcomes

Preliminary studies suggest that Sermorelin may lead to an increase in average growth hormone levels by up to 82%, with effects lasting around two hours. Another study over 16 weeks suggested that Sermorelin could elevate growth hormone levels by 107% and IGF-1 levels by 28%. These increases were associated with a gain in lean body mass and an unchanged fat mass, potentially due to Sermorelin’s capacity to boost growth hormone and IGF-1, which are known for their anabolic effects.

Effects on Lipodystrophy

In a controlled study involving 31 HIV-positive subjects with lipodystrophy, Sermorelin administration led to significant increases in growth hormone levels compared to a placebo. This resulted in increased lean body mass and reduced abdominal visceral fat, as well as a lower trunk-to-lower extremity fat ratio, without significant changes in glucose or insulin levels.

Cognitive Function and Aging

Studies conducted in the early 2000s with subjects aged 68 to 69 explored the relationship between declining growth hormone levels and cognitive impairment. The introduction of Sermorelin appeared to improve cognitive performance, as measured by the Wechsler Adult Intelligence Scale (WAIS), including IQ, picture arrangement, and verbal tests.

Potential Anti-Tumor Effects

A clinical study involving 1,018 glioma patients evaluated the response to over 4,000 compounds, including Sermorelin. The peptide appeared to induce significant sensitivity in the test subjects, suggesting it may inhibit tumor cell cycles and prevent proliferation.

Hypogonadism and Testosterone Production

Initial research suggested that Sermorelin could increase lean mass and potentially benefit individuals with hypogonadism. In one study, test subjects were divided into two groups, receiving either Sermorelin followed by GHRH 1-40 or the reverse sequence. The peptide seemed to stimulate the release of FSH and LH, which might enhance testosterone production. Subsequent studies, including a clinical trial with male subjects aged 22 to 33 and 60 to 78, indicated that Sermorelin increased testosterone levels, particularly at night.

Sermorelin peptide is available strictly for research and laboratory use.